MedTrace Logo

Propofol-Dexmedetomine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery :Effect on Anesthetic Consumption ,Perioperative Outcomes,and Early Recovery

NCT07798089 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-09-01

No results posted yet for this study

Summary

Propofol-Dexmedetomidine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery: Effects on Anesthetic Consumption, perioperative outcomes, and Early Recovery

Conditions

  • Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery

Interventions

DRUG

Propofol (Astra-Zeneca)

Thirty patients will receive a continuous infusion of propofol at a rate of 2 mg/kg/h and 50 cc 0.9% sodium chloride solution infused at a rate of 0.4 µg/kg/h (used as a placebo).

DRUG

propofol and dexmetomidine

patients will receive a continuous infusion of propofol at a rate of 2 mg/kg/h in addition to dexmedetomidine at a rate of 0.4 µg/kg/h.

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2026-12-01
Completion
2027-01-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07798089 on ClinicalTrials.gov